Skip to main content
. Author manuscript; available in PMC: 2014 Nov 14.
Published in final edited form as: Immunity. 2013 Oct 24;39(5):10.1016/j.immuni.2013.10.006. doi: 10.1016/j.immuni.2013.10.006

Figure 4. bvPLA2 and LPC induce IL-33 release and activation of ILC2s.

Figure 4

(A and C) IL-33 concentration in peritoneal fluid after (A) bvPLA2 and (C) LPC intraperitoneal immunizations. (B and D) IL-33 concentration in supernatants of cells overexpressing IL-33 after stimulation with (B) bvPLA2 and (D) LPC. (E) Peritoneal exudate collected from WT and Il1rl1−/− (ST2-deficient) mice on day 4 after daily intraperitoneal injections with PLA2 for 3 days. FACS plots show group 2 innate lymphoid cells, as defined by CD45+Lin-CD90.2+, after ex vivo stimulation with PMA and ionomycin to induce cytokine production. Eosinophils, mast cells and neutrophils were defined by morphology (n=5 mice/group). All error bars show s.e.m. *P<0.05; **P<0.005; ***P<0.001. Data are representative of at least two experiments. See also Figure S3.